183 related articles for article (PubMed ID: 32920985)
1. Impact of gene polymorphisms in drug-metabolizing enzymes and transporters on trough concentrations of rivaroxaban in patients with atrial fibrillation.
Nakagawa J; Kinjo T; Iizuka M; Ueno K; Tomita H; Niioka T
Basic Clin Pharmacol Toxicol; 2021 Feb; 128(2):297-304. PubMed ID: 32920985
[TBL] [Abstract][Full Text] [Related]
2. Impacts of pregnane X receptor and cytochrome P450 oxidoreductase gene polymorphisms on trough concentrations of apixaban in patients with non-valvular atrial fibrillation.
Nakagawa J; Kinjo T; Aiuchi N; Ueno K; Tomita H; Niioka T
Eur J Clin Pharmacol; 2023 Jan; 79(1):127-135. PubMed ID: 36399204
[TBL] [Abstract][Full Text] [Related]
3. Population pharmacokinetics and pharmacogenomics of apixaban in Japanese adult patients with atrial fibrillation.
Ueshima S; Hira D; Kimura Y; Fujii R; Tomitsuka C; Yamane T; Tabuchi Y; Ozawa T; Itoh H; Ohno S; Horie M; Terada T; Katsura T
Br J Clin Pharmacol; 2018 Jun; 84(6):1301-1312. PubMed ID: 29457840
[TBL] [Abstract][Full Text] [Related]
4. Impact of ABCB1, ABCG2, and CYP3A5 polymorphisms on plasma trough concentrations of apixaban in Japanese patients with atrial fibrillation.
Ueshima S; Hira D; Fujii R; Kimura Y; Tomitsuka C; Yamane T; Tabuchi Y; Ozawa T; Itoh H; Horie M; Terada T; Katsura T
Pharmacogenet Genomics; 2017 Sep; 27(9):329-336. PubMed ID: 28678049
[TBL] [Abstract][Full Text] [Related]
5. The impact of ABCB1, CYP3A4/5 and ABCG2 gene polymorphisms on rivaroxaban trough concentrations and bleeding events in patients with non-valvular atrial fibrillation.
Wu T; Wu S; Li L; Xiang J; Wang N; Chen W; Zhang J
Hum Genomics; 2023 Jul; 17(1):59. PubMed ID: 37420302
[TBL] [Abstract][Full Text] [Related]
6. Effect of CYP3A4, CYP3A5, ABCB1 Gene Polymorphisms on Rivaroxaban Pharmacokinetics in Patients Undergoing Total Hip and Knee Replacement Surgery.
Sychev D; Minnigulov R; Bochkov P; Ryzhikova K; Yudina I; Lychagin A; Morozova T
High Blood Press Cardiovasc Prev; 2019 Oct; 26(5):413-420. PubMed ID: 31617197
[TBL] [Abstract][Full Text] [Related]
7. Drug interactions and pharmacogenetic factors contribute to variation in apixaban concentration in atrial fibrillation patients in routine care.
Gulilat M; Keller D; Linton B; Pananos AD; Lizotte D; Dresser GK; Alfonsi J; Tirona RG; Kim RB; Schwarz UI
J Thromb Thrombolysis; 2020 Feb; 49(2):294-303. PubMed ID: 31564018
[TBL] [Abstract][Full Text] [Related]
8. Influence of CYP3A4/5 and ABC transporter polymorphisms on lenvatinib plasma trough concentrations in Japanese patients with thyroid cancer.
Ozeki T; Nagahama M; Fujita K; Suzuki A; Sugino K; Ito K; Miura M
Sci Rep; 2019 Apr; 9(1):5404. PubMed ID: 30931962
[TBL] [Abstract][Full Text] [Related]
9. Influence of ABCB1, CYP3A5 and CYP3A4 gene polymorphisms on prothrombin time and the residual equilibrium concentration of rivaroxaban in patients with non-valvular atrial fibrillation in real clinical practice.
Sychev DA; Sokolov AV; Reshetko OV; Fisenko VP; Sychev IN; Grishina EA; Bochkov PO; Shevchenko RV; Abdullaev SP; Denisenko NP; Ivashchenko DV; Sozaeva ZA; Kachanova AA
Pharmacogenet Genomics; 2022 Dec; 32(9):301-307. PubMed ID: 36256705
[TBL] [Abstract][Full Text] [Related]
10. Effect of tacrolimus dispositional genetics on acute rejection in the first 2 weeks and estimated glomerular filtration rate in the first 3 months following kidney transplantation.
Hu R; Barratt DT; Coller JK; Sallustio BC; Somogyi AA
Pharmacogenet Genomics; 2019 Jan; 29(1):9-17. PubMed ID: 30489455
[TBL] [Abstract][Full Text] [Related]
11. Effects of polymorphisms in NR1I2, CYP3A4, and ABC transporters on the steady-state plasma trough concentrations of bosutinib in Japanese patient with chronic myeloid leukemia.
Abumiya M; Mita A; Takahashi S; Yoshioka T; Kameoka Y; Takahashi N; Miura M
Med Oncol; 2018 May; 35(6):90. PubMed ID: 29736778
[TBL] [Abstract][Full Text] [Related]
12. Clinical evaluation of laboratory methods to monitor exposure of rivaroxaban at trough and peak in patients with atrial fibrillation.
Al-Aieshy F; Malmström RE; Antovic J; Pohanka A; Rönquist-Nii Y; Berndtsson M; Al-Khalili F; Skeppholm M
Eur J Clin Pharmacol; 2016 Jun; 72(6):671-9. PubMed ID: 27066956
[TBL] [Abstract][Full Text] [Related]
13. Determinants of gefitinib pharmacokinetics in healthy Chinese male subjects: A pharmacogenomic study of cytochrome p450 enzymes and transporters.
Wan Z; Guo L; Li P; Zhao Z; Xu B; Ren L; Yan Y; Liu H; Zhang Y; Liu L
J Clin Pharm Ther; 2020 Oct; 45(5):1159-1167. PubMed ID: 32562509
[TBL] [Abstract][Full Text] [Related]
14. Downregulation of ABCB1 gene in patients with total hip or knee arthroplasty influences pharmacokinetics of rivaroxaban: a population pharmacokinetic-pharmacodynamic study.
Zdovc J; Petre M; Pišlar M; Repnik K; Mrhar A; Vogrin M; Potočnik U; Grabnar I
Eur J Clin Pharmacol; 2019 Jun; 75(6):817-824. PubMed ID: 30725221
[TBL] [Abstract][Full Text] [Related]
15. ABCB1, ABCG2 and CYP2D6 polymorphism effects on disposition and response to long-acting risperidone.
Ganoci L; Trkulja V; Živković M; Božina T; Šagud M; Lovrić M; Božina N
Prog Neuropsychopharmacol Biol Psychiatry; 2021 Jan; 104():110042. PubMed ID: 32682874
[TBL] [Abstract][Full Text] [Related]
16. Effects of pharmacogenetic variants on vemurafenib-related toxicities in patients with melanoma.
Goey AK; With M; Agema BC; Hoop EO; Singh RK; van der Veldt AA; Mathijssen RH; van Schaik RH; Bins S
Pharmacogenomics; 2019 Dec; 20(18):1283-1290. PubMed ID: 31829834
[No Abstract] [Full Text] [Related]
17. Effect of ABCB1 gene variants on rivaroxaban pharmacokinetic and hemorrhage events occurring in patients with non-valvular atrial fibrillation.
Zhang D; Qin W; Du W; Wang X; Chen W; Li P
Biopharm Drug Dispos; 2022 Aug; 43(4):163-171. PubMed ID: 35940587
[TBL] [Abstract][Full Text] [Related]
18. Association of ABCG2 polymorphism with clinical efficacy of imatinib in patients with gastrointestinal stromal tumor.
Koo DH; Ryu MH; Ryoo BY; Beck MY; Na YS; Shin JG; Lee SS; Kim EY; Kang YK
Cancer Chemother Pharmacol; 2015 Jan; 75(1):173-82. PubMed ID: 25417047
[TBL] [Abstract][Full Text] [Related]
19. The Influence of ABCB1 (rs1045642 and rs4148738) Gene Polymorphisms on Rivaroxaban Pharmacokinetics in Patients Aged 80 Years and Older with Nonvalvular Atrial Fibrillation.
Sychev D; Ostroumova O; Cherniaeva M; Shakhgildian N; Mirzaev K; Abdullaev S; Denisenko N; Sozaeva Z; Kachanova A; Gorbatenkova S; Shastina V
High Blood Press Cardiovasc Prev; 2022 Sep; 29(5):469-480. PubMed ID: 35960493
[TBL] [Abstract][Full Text] [Related]
20. Physiologically-Based Pharmacokinetic Modeling for the Prediction of a Drug-Drug Interaction of Combined Effects on P-glycoprotein and Cytochrome P450 3A.
Otsuka Y; Choules MP; Bonate PL; Komatsu K
CPT Pharmacometrics Syst Pharmacol; 2020 Nov; 9(11):659-669. PubMed ID: 33030266
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
